The pharmaceutical industry is currently sinking considerable resources into the treatment of autoimmune disorders. One new candidate target is the histone deacetylase, HDAC7, reviewed in LeadDiscoveryâ€™s Target of the Month for July. HDAC7 inhibits Nur77 expression, a key regulator of T cell receptor mediated T cell apoptosis. Blocking HDAC7 can potentialy enhance apoptosis of autoreactive T cells and HDAC7 inhibitors may therefore be candidate treatments of autoimmune disorders.
Biogen and Idec Pharmaceuticals are set to merge in a stock-for-stock transaction valued at over $6.6 billion following announcements made earlier this week. The deal will create the third largest biotech firm in the world, yet Wall Street has so far appeared unimpressed by the deal. Even individual analysts seem to be disagreeing as to the strategic sense of the partnership.
At every stage of the R&D process, the companies must evaluate the time, logistics, expense and expertise that they can allocate. This also entails knowing when to rely on in-house capabilities and wh
Dr Faiz Kermani
Uncontrolled proliferation is a common feature of malignant cells. Proliferation correlates with a nuclear protein known as Ki-67. Researchers have now shown that an antisense oligonucleotide against
To mark the American Society of Clinical Oncology's 2003 conference, LeadDiscovery has launched The Oncology Collection. The Oncology Collection groups all of LeadDiscovery's oncology services in one
Statins have become the gold standard in the treatment of dyslipidemia, accounting for approximately 60% of treatments prescribed to patients with coronary heart disease in the late 1990s. However, wi
Eli Lilly and Company is set to launch Cymbalta into the depression and stress urinary incontinence markets in mid-2003. Datamonitor analyzes whether the company most synonymous with the antidepressan
Switzerland has been a major force in the development of new medicines for over a century. Around 5% of current global pharmaceutical R&D is attributable to Swiss companies.
Larry Hughes and Dr Faiz Kermani
The healthcare industry has utilized the Internet most recently as both a marketing tool and as a facility to pass on important medical information. Leading drug maker Abbott Laboratories will be look
Over the past decade, behavioral disorders have received increasing attention, both from the media and medical professionals, however only attention deficit/hyperactivity disorder has emerged as a key
Enterprise Incentive Management (EIM) software -improves pharmaceutical sales and provides accurate and timely compensation to both direct and indirect sales people. Already used in the pharmaceutica
The development of novel medicines is critical if diseases and disorders are to be effectively treated. As a result, many have looked to biotechnology to provide continuing innovation in the field of
Pietro Bonacossa and Dr Faiz Kermani
Investing in R&D requires long-term planning and the willingness to take risks. Only about 15% of new drugs entering development subsequently reach the market, and the overall expense can be in the or
Faiz Kermaini & Pietro Bonacossa
Asthma drives a large but competitive market. Current therapeutics are generally effective but patient compliance is often poor. Future commercial successes in the asthma arena will likely focus on mo
LeadDiscovery/Prof. Peter Barnes
Roche's recent announcement of an EU price point of $20,570 per year for its novel HIV fusion inhibitor Fuzeon has brought the issue of pricing HIV therapies to the fore. Roche's premium pricing strat
Approximately 9% of the US population suffers from moderate to severe non-cancer-related pain, a figure that includes 40-70 million individuals with chronic pain. The development of analgesics represe
Considerable evidence exists linking the retinoids to amyloid expression and neural responses to amyloid. Retinoic acid derivative may thus offer a therapeutic avenue for Alzheimer's disease
While the Internet continued to be used for important reference and record keeping purposes, its power as a communications medium was perhaps most evident by the websites being set up to help those wo
Ever since receiving FDA approval for Aredia in September 1998 Novartis has held the gold standard treatment for bone metastases. In Zometa the Swiss pharmaceutical company possesses a more potent, ne
The considerable investment and overheads required for the development of new drugs mean that pharmaceutical companies must establish brand loyalty throughout a productâ€™s lifecycle in order to protect
Physicians, patients and even healthcare companies were equally well catered for by a number of important eHealth announcements that came to light in the past fortnight. The prospect of remote medical
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her